Capricor Therapeutics Inc Share Price OTC Bulletin Board
Stocks
CAPR
US14070B1017
Biotechnology & Medical Research
| Market Cap | 1.18B 1.03B 951M 874M 1.66B 113B 1.68B 11.35B 4.45B 55.43B 4.43B 4.33B 191B | P/E 2026 * |
-34.4x | P/E 2027 * | -31.1x |
|---|---|---|---|---|---|
| Enterprise Value | 1.18B 1.03B 951M 874M 1.66B 113B 1.68B 11.35B 4.45B 55.43B 4.43B 4.33B 191B | EV / Sales 2026 * |
9.98x | EV / Sales 2027 * | 9.63x |
| Free-Float |
90.53% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Capricor Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 62 | 19/11/2013 |
Anthony Bergmann
DFI | Director of Finance/CFO | 40 | 31/12/2017 |
Michael Binks
CTO | Chief Tech/Sci/R&D Officer | - | 12/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Frank Litvack
CHM | Chairman | 70 | 31/10/2013 |
David Musket
BRD | Director/Board Member | 68 | 19/11/2013 |
George Dunbar
BRD | Director/Board Member | 79 | 19/11/2013 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 1.18B | |
| +3.13% | +13.95% | +64.21% | +94.35% | 57.82B | |
| -0.61% | -6.43% | +53.42% | +70.38% | 53.71B | |
| -0.27% | -5.77% | +6.75% | +433.06% | 23.8B | |
| +1.76% | -1.65% | -16.86% | -15.01% | 23.26B | |
| -0.56% | +6.10% | +44.56% | -3.75% | 20.7B | |
| -0.87% | -2.51% | +33.77% | -29.95% | 17.81B | |
| +10.00% | -4.30% | +208.33% | +370.99% | 16.9B | |
| -2.61% | +10.00% | +47.02% | +699.54% | 16.36B | |
| -0.39% | -1.00% | +26.08% | +186.49% | 13.96B | |
| Average | +0.95% | +1.42% | +51.92% | +200.68% | 27.15B | |
| Weighted average by Cap. | +1.11% | +1.35% | +51.27% | +159.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 118M 103M 95.23M 87.54M 166M 11.36B 169M 1.14B 446M 5.55B 443M 434M 19.14B | 122M 107M 98.67M 90.7M 172M 11.77B 175M 1.18B 462M 5.75B 459M 449M 19.83B |
| Net income | -28.4M -24.83M -22.91M -21.06M -39.9M -2.73B -40.58M -273M -107M -1.34B -107M -104M -4.6B | -48.17M -42.11M -38.85M -35.71M -67.67M -4.63B -68.82M -464M -182M -2.27B -181M -177M -7.81B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
